Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
In light of uncertainties arising from the situation in the Middle East, it is difficult to make a reasonable estimate of potential changes to production plans and changes in raw material costs. The company will promptly disclose the impact once it becomes clear.
Loss on disposal of fixed assets: ¥1 million (fiscal year ended March 2026). The previous fiscal year included an impairment loss of ¥516 million, among other items.
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥11,600 million（5.5% increase year on year） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue: ¥10,993 million; operating profit: ¥739 million; ordinary profit: ¥825 million; net profit attributable to owners of the parent: ¥781 million |
| Reason for the revision | In light of uncertainties arising from the situation in the Middle East, it is difficult to make a reasonable estimate of potential changes to production plans and changes in raw material costs. The company will promptly disclose the impact once it becomes clear. |
| Details and amount of extraordinary loss | Loss on disposal of fixed assets: ¥1 million (fiscal year ended March 2026). The previous fiscal year included an impairment loss of ¥516 million, among other items. |
| Dividend forecast revision | The year-end dividend for the fiscal year ended March 2026 will be increased by ¥2.50 from the initial forecast to ¥7.50 per share. For the fiscal year ending March 2027, the company plans an interim dividend of ¥7.50 per share and a year-end dividend of ¥7.50 per share, for a total of ¥15.00 per share. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fine chemicals business, results benefited from large-scale projects and large spot projects in the pharmaceutical field, as well as newly developed semiconductor-related products. In the flame retardants business, contributions came from firm demand and a review of selling prices, while the health support business benefited from stable demand and a review of selling prices. The company is not disclosing an earnings forecast for the fiscal year ending March 2027 because it is difficult to make a reasonable estimate of potential changes to production plans arising from the situation in the Middle East and changes in raw material costs.